Bimekizumab maintains complete skin clearance in 73% of psoriasis patients at 4 years
Can psoriasis treatment keep skin clear for years? New data suggests it might.
A pooled analysis of phase 3 trials and open-label extension in 503 psoriasis patients found 73.0% of those achieving complete clearance at …
After four years on bimekizumab, about 73% of patients with psoriasis kept their skin completely clear, suggesting the treatment may help re…
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
Could a new psoriasis treatment work better by targeting two inflammation sources at once?
A Phase 2a, multicenter, randomized, subject- and investigator-blind study investigated the pharmacokinetics, pharmacodynamics, and safety o…
A new psoriasis drug targets two inflammation sources to see if it works better for thick, scaly skin patches in adults.
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis
Can a new psoriasis drug outperform an established treatment?
A phase 3 randomized controlled trial enrolled 567 adults with moderate to severe chronic plaque psoriasis to compare bimekizumab against pl…
A new psoriasis drug called bimekizumab is being tested against existing treatments in a major trial involving 567 adults to see if it helps…
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
Can a new drug help people with moderate to severe plaque psoriasis?
A phase 3 randomized controlled trial evaluated bimekizumab versus placebo in 435 adults with moderate to severe chronic plaque psoriasis. T…
A new drug tested in a large study aims to help clear skin for people with moderate to severe plaque psoriasis.